Exploring Darolutamide and Its Implications in Oncology Pharmacy

This chapter explores a study on darolutamide, an androgen antagonist anticipated to gain FDA approval alongside enzalutamide and apalutamide. It discusses potential drug interactions with statins, particularly in older men with prostate cancer, and invites audience engagement for future oncology pharmacy topics.